Increased osteoblastic activity and expression of receptor activator of NF-κB ligand in nonuremic nephrotic syndrome

Journal of the American Society of Nephrology

Volumn 16, Issue 7, 2005, Pages 2198-2204

  Freundlich, Michael ^a,b,d   Alonzo, Evelyn ^c   Bellorin Font, Ezequiel ^c   Weisinger, Jose R ^c  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Pediatric Specialty Center   (United States)

^c HOSPITAL UNIVERSITARIO DE CARACAS   (Venezuela)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CORTICOSTEROID; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE; CARRIER PROTEIN; MEMBRANE PROTEIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TNFRSF11A PROTEIN, HUMAN; TNFSF11 PROTEIN, HUMAN;

ARTICLE; BONE DEVELOPMENT; CHEMICAL ANALYSIS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; NEPHROTIC SYNDROME; OSSIFICATION; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RELAPSE; REMISSION; UPREGULATION; BIOSYNTHESIS; CELL CULTURE; METABOLIC BONE DISEASE; METABOLISM; OSTEOBLAST; PRESCHOOL CHILD; UREMIA;

BONE DISEASES, METABOLIC; CARRIER PROTEINS; CELLS, CULTURED; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; NEPHROTIC SYNDROME; OSTEOBLASTS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; UREMIA;

EID: 27744503395     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2004121062     Document Type: Article

References (49)

1. Goldstein DA, Haldiman B, Shermann D, Norman AW, Massry SG: Vitamin D metabolites and calcium metabolism in patients with nephrotic syndrome and normal renal function. J Clin Endocrinol Metab 52: 116-121, 1981
2. Lambert PW, Deoreo PB, Fu IY, Kaetzel DM, Vonahn K, Hollis BW, Roos BA: Urinary and plasma vitamin D3 metabolites in the nephrotic syndrome. Metab Bone Dis Relat Res 4: 7-15, 1982
3. Freundlich M, Bourgoignie JJ, Zilleruelo G, Jacob AI, Canterbury JM, Strauss J: Bone modulating factors in nephrotic children with normal glomerular filtration rate. Pediatrics 76: 280-285, 1985
4. Alon U, Chan JCM: Calcium and vitamin D homeostasis in the nephrotic syndrome: Current status. Nephron 36: 1-4, 1984
5. Lim P, Jacob E, Tock EPC, Pwee HS: Calcium and phosphorus metabolism in nephrotic syndrome. Q J Med 183: 327-338, 1977
6. Goldstein DA, Oda Y, Korokawa K, Massry SG: Blood levels of 25-hydroxyvitamin D in nephrotic syndrome. Ann Intern Med 87: 664-667, 1977
7. Schmidt-Gayk H, Grawunder C, Tschöpe W, Schmitt W, Ritz E, Pietsch V, Andrassy K, Bouillon R: 25-hydroxyvitamin D in nephrotic syndrome. Lancet 2: 105-108, 1977
8. Lettgen B, Jeken C, Reiners C: Influence of steroid medication on bone mineral density in children with nephrotic syndrome. Pediatr Nephrol 8: 667-670, 1994
9. Malluche HH, Goldstein DA, Massry SG: Osteomalacia and hyperparathyroid bone disease in patients with nephrotic syndrome. J Clin Invest 63: 494-500, 1979
10. Tessitore N, Bonucci E, D'Angelo A, Lund B, Corgnati A, Lund B, Valvo E, Lupo A, Loschiavo C, Fabris A, Maschio G: Bone histology and calcium metabolism in patients with nephrotic syndrome and normal or reduced renal function. Nephron 37: 153-159, 1984
11. Kuizon BD, Goodman WG, Jüppner H, Boechat I, Nelson P, Gales B, Salusky I: Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD. Kidney Int 53: 205-211, 1998
12. Srivastava T, Simon SD, Alon US: High incidence of focal segmental glomerulosclerosis in nephrotic syndrome of childhood. Pediatr Nephrol 13: 13-18, 1999
13. Bonilla-Felix M, Parra C, Dajani T, Ferris M, Swinford RD, Portman RJ: Changing patterns in the histopathology of idiopathic nephrotic syndrome in children. Kidney Int 55: 1885-1890, 1999
14. Baum MA, Stablein DM, Panzarino VM, Tejani A, Harmon WE, Alexander SR: Loss of living donor renal allograft survival advantage in children with focal segmental glomerulosclerosis. Kidney Int 59: 328-333, 2001
15. Freundlich M, Bourgoignie JJ, Zilleruelo G, Abitbol C, Canterbury JM, Strauss J: Calcium and vitamin D metabolism in children with nephrotic syndrome. J Pediatr 108: 383-387, 1986
16. Manolagas SC, Jilka RL: Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 332: 305-311, 1995
17. Hruska KA, Teitelbaum SL: Renal osteodystrophy. N Engl J Med 333: 166-174, 1995
18. Hofbauer LC, Heufelder AE: Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med 79: 243-253, 2001
19. Saxena S, Mittal A, Andal A: Pattern of interleukins in minimal change nephrotic syndrome of childhood. Nephron 65: 56-61, 1993
20. Neuhaus TJ, Wadhwa M, Callard R, Barrat M: Increased IL-2, IL-4 and interferon-gamma (IFN-gamma) in steroid-sensitive nephrotic syndrome. Clin Exp Immunol 100: 475-479, 1995
21. Bustos C, Gonzalez E, Muley R, Alonso JL, Egido J: Increase of tumor necrosis factor alpha synthesis and gene expression in peripheral blood mononuclear cells of children with idiopathic nephrotic syndrome. Eur J Clin Invest 24: 799-805, 1994
22. Barnett HL, Schoeneman M, Bernstein J, Edelman CM Jr: The nephrotic syndrome. In: Pediatric Kidney Disease, edited by Edelman CM Jr, Boston, Little, Brown & Co., 1978, pp 679-695
23. Abitbol C, Zilleruelo G, Freundlich M, Strauss J: Quantitation of proteinuria with urinary protein/creatinine ratios and random testing with dipsticks in nephrotic children. J Pediatr 116: 243-247, 1990
24. Tommasi M, Bacciottini L, Benucci A, Brocchi A, Passeri A, Saracini D, D'Agata A, Cappelli G: Serum biochemical markers of bone turnover in healthy infants and children. Int J Biol Markers 11: 159-164, 1996
25. Mora S, Pitukcheewanont P, Kaufman FR, Nelson JC, Gilsanz V: Biochemical markers of bone turnover and the volume of the density of bone in children at different stages of sexual development. J Bone Miner Res 14: 1664-1671, 1999
26. Gertz BJ, Clemens JD, Holland SD, Yuan W, Greenspan S: Application of a new serum assay for type I collagen cross-linked N-telopeptides: Assessment of diurnal changes in bone turnover with and without alendronate treatment. Calcif Tissue Int 63: 102-106, 1998
27. Nussbaum SR, Zaradnick RJ, Lavigne JR, Brennan GL, Nozawaung C, Kim LY, Keutman T, Wang CA, Potts JT Jr, Segre GV: Highly sensitivity two-site immunoradiometric assay of parathyroid, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 33: 1364-1367, 1987
28. Sabokbar A, Millett PJ, Myer B, Rushton N: A rapid, quantitative assay for measuring alkaline phosphatase activity in osteoblastic cells in vitro. Bone Miner 27: 57-67, 1994
29. Mittal SK, Dash SC, Tiwari SC, Agarwal SK, Saxena S, Fishbane S: Bone histology in patients with nephrotic syndrome and normal renal function. Kidney Int 55:1912-1919, 1999
30. Korkor A, Schwartz J, Bergfeld M, Teitelbaum S, Avioli L, Klahr S, Slatopolsky E: Absence of metabolic bone disease in adult patients with nephrotic syndrome and normal renal function. J Clin Endocrinol Metab 56: 496-500, 1983
31. Huang JC, Sakata T, Pfleger LL, Bencsik M, Halloran BP, Bikle DD, Nissenson RA: PTH differentially regulates expression of RANKL and OPG. J Bone Miner Res 19: 235-244, 2004
32. Calvo MS, Eyre DR, Gundberg CM: Molecular basis and clinical application of biological markers of bone turnover. Endocr Rev 17: 333-368, 1996
33. Hofbauer LC, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S: Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochem Biophys Res Commun 250: 776-781, 1998
34. Kurokouchi K, Kambe F, Yasukawa K, Izumi R, Ishiguro N, Iwata H, Seo H: TNF-alpha increases expression of IL-6 and ICAM-1 genes through activation of NF-kappaB in osteoblast-like ROS17/2.8 cells. J Bone Miner Res 13: 1290-1299, 1998
35. Adebanjo OA, Moonga BS, Yamate T, Sun L, Minkin C, Abe E, Zaidi M: Mode of action of interleukin-6 on mature osteoclasts. Novel interactions with extracellular Ca2+ sensing in the regulation of osteoclastic bone resorption. J Cell Biol 142: 1347-1356, 1998
36. Daniel V, Trautman Y, Konrad M, Nayir A, Scharer K: T-lymphocyte populations, cytokines and other growth factors in serum and urine of children with idiopathic nephrotic syndrome. Clin Nephrol 47: 289-297, 1997
37. Freundlich M, Joffe M, Goodman WW, Salusky I: Bone histology in steroid-treated children with non-azotemic nephrotic syndrome. Pediatr Nephrol 19: 400-407, 2004
38. Sahali D, Pawlak A, Gouvello SL, Lang P, Valanciute A, Remy P, Loirat C, Niaudet P, Bensman A, Guellaen G: Transcriptional and post-transcriptional alterations of IkappaBalpha in active minimal-change nephrotic syndrome. J Am Soc Nephrol 12: 1648-1658, 2001
39. Disthabanchong S, Martin KJ, McConkey CL, Gonzalez EA: Metabolic acidosis up-regulates PTH/PTHrP receptors in UMR 106-01 osteoblast-like cells. Kidney Int 62: 1171-1177, 2002
40. Frick KK, Bushinsky DA: Metabolic acidosis stimulates RANK ligand RNA expression in bone through a cyclooxygenase dependent mechanism. J Bone Miner Res 18: 317-1325, 2003
41. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC: Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. J Clin Invest 102: 274-282, 1998
42. Rojas E, Carlini RG, Clesca P, Arminio A, Zuniaga O, Elquezabal K, Weisinger JR, Hruska KA, Bellorin-Font E: The pathogenesis of osteodystrophy after renal transplantation detected by early alterations in bone remodeling. Kidney Int 63: 1915-1923, 2003
43. Monier-Faugere MC, Mawad H, Quanle Q, Friedler RM, Malluche HH: High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation. J Am Soc Nephrol 11: 1093-1099, 2000
44. Olgaard K, Storm T, Wowern NV, Daugaard H, Egfjord M, Lewin E, Brandi L: Glucocorticoid-induced osteoporosis in the lumbar spine, forearm, and mandible of nephrotic patients: A double-blind study on the high-dose, long-term effects of prednisone versus deflazacort. Calcif Tissue Int 50: 490-497, 1992
45. Chesney RW, Mazess RB, Rose P, Jax DK: Effect of prednisone on growth and bone mineral content in childhood glomerular disease. Am J Dis Child 132: 768-772, 1978
46. Leonard MB, Feldman HI, Shults J, Zemel BS, Foster BJ, Stallings VA: Long-term, high-dose glucocorticoids and bone mineral content in childhood glucocorticoid-sensitive nephrotic syndrome. N Engl J Med 351: 868-875, 2004
47. Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, Khosla S: Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: Potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 140: 4382-4389, 1999
48. Sprague SM: Mechanisms of transplantation-associated bone loss. Pediatr Nephrol 14: 650-653, 2000
49. Westeel FP, Mazouz H, Ezaitouni F, Hottelart C, Ivan C, Fardelone P, Brazier M, El Esper I, Petit J, Achard JM, Pruna A, Fournier A: Cyclosporine bone remodelling effect prevents steroid osteopenia after kidney transplantation. Kidney Int 58: 1788-1796, 2000